Revenue
2016
2017
2018
2019
2024
2025
Monopar Therapeutics (MNPR)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | $0 | $0 | $0 | $0 |
| Research & development | $9.9M | $13.0M | $5.6M | $7.6M | $6.5M | $4.1M | $2.0M | $1.8M | $935,319 | $280,355 |
| Operating expenses | $16.7M | $16.2M | $8.8M | $10.5M | $9.1M | $6.5M | $4.3M | $3.3M | $16.6M | $1.2M |
| Operating income | −$16.7M | −$16.2M | −$8.8M | −$10.5M | −$9.1M | −$6.5M | −$4.3M | −$3.3M | −$16.6M | −$1.2M |
| Net income | −$13.7M | −$15.6M | −$8.4M | −$10.5M | −$9.1M | −$6.3M | −$4.2M | −$3.2M | −$16.6M | −$1.2M |
| Basic EPSper diluted share | -$1.85 | -$4.11 | -$3.04 | -$0.83 | -$0.73 | -$0.58 | -$0.45 | -$0.35 | -$1.89 | — |
| Diluted EPSper diluted share | — | — | — | — | -$0.73 | -$0.58 | -$0.45 | -$0.35 | -$1.89 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 26, 2025Form 4 | Vu Quan AnhChief Financial Officer | BuyCommon Stock | 1.5K | $69.95 | $104.9K | 1.5K |
| Dec 18, 2025Form 4 | KLAUSNER ARTHUR JDirector | SellCommon Stock | 461 | $68.09 | $31.4K | 8.8K |
| Dec 18, 2025Form 4 | KLAUSNER ARTHUR JDirector | SellCommon Stock | 4.7K | $67.06 | $312.5K | 9.2K |
| Sep 24, 2025Form 4 | Tactic Pharma LLC +4Chief Executive Officer | SellCommon Stock | 550.2K | $63.61 | $35.00M | 272.0K |
| Jul 14, 2025Form 4 | Tsuchimoto Kim RDirector | SellCommon Stock | 8.9K | $40.00 | $356.2K | 11.5K |